Roivant Sciences Ltd.
StreetZero Signal 67
About Roivant Sciences Ltd.
Roivant Sciences Ltd. (Nasdaq: ROIV) is a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Its mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building agile, focused subsidiary companies called Vants.
LATEST FUNDINGRule 144
$7.0M
Announced 2026-10-20
TOTAL RAISED$1.3B
IN THE NEWS
- 🔗 Roivant Sciences Announces Proposed Public Equity Offering | Roivant Sciences Ltd.
- 🔗 Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering | Roivant Sciences Ltd.
- 🔗 Roivant Sciences - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Roivant Sciences - Wikipedia
- 🔗 Roivant Sciences to go public through $7.3 billion SPAC deal | STAT
EMPLOYEES—
FOUNDED—
HQLondon, United Kingdom
Industry
Public Equity (NASDAQ)
Tags
BiopharmaceuticalPublicBiotech
Investors
Key highlights
- Completed $150M public equity offering in November 2022 with $100M gross proceeds to the company.
- Went public via $7.3B SPAC merger in 2021 trading as ROIV on Nasdaq.
- Raised over $1.3B across multiple rounds including $1B in 2019.
- Operates with multiple focused subsidiary Vants to accelerate drug development.
Ask StreetZero about Roivant Sciences Ltd.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account